The immune balance between memory and regulatory B cells in NMO and the changes of the balance after methylprednisolone or rituximab therapy
The immune balance between memory and regulatory B cells in NMO and the changes of the balance after methylprednisolone or rituximab therapy
复制标题
NMO记忆与调节B细胞的免疫平衡及甲泼尼龙或利妥昔单抗治疗后平衡的变化
DOI：
10.1016/j.jneuroim.2015.03.016
复制
发表时间：
2015-05-15
影响因子：
3.3
通讯作者：
Lu, Chuanzhen
中科院分区：
文献类型：
--
作者：
Quan, Chao;ZhangBao, Jingzi;Lu, Chuanzhen
我们的目的是探讨大剂量甲基强的松龙治疗（HDMT）和利妥昔单抗对NMO患者循环B细胞的影响。22例急性复发期NMO患者接受HDMT治疗，9例缓解期患者接受利妥昔单抗治疗。用流式细胞仪检测治疗前后外周血中CD 19（+）CD 27（+）记忆B细胞（BcM）、CD 19（+）CD 24（high）CD 38（high）调节性B细胞（布雷格）的比例及B细胞产生白细胞介素（IL）-10和干扰素（IFN）-γ的情况。与健康对照组相比，在HDMT之前，NMO患者的循环中BCLs的频率和B细胞IL-10的产生显著降低。两周的HDMT进一步降低了Bleg的频率，而增加了Bleg的频率，这使得Bleg和布雷格之间的数量平衡有利于Bleg。同时，HDMT显著抑制B细胞IFN-γ的表达。利妥昔单抗通过消除B细胞和随后的B细胞再增殖发挥其作用，其特征在于Bleg占优势，将布雷格和Bleg之间的数量平衡恢复到有利的“布雷格> Bleg”状态。因此，HDMT和利妥昔单抗对NMO中B细胞的影响基本不同。(C)2015 Elsevier B. V.版权所有。
We aim to explore the impacts of high dose methylprednisolone therapy (HDMT) and rituximab on circulating B cells in NMO patients. Twenty-two NMO patients in the acute relapse phase were treated with HDMT and 9 patients in the remission stage were treated with rituximab. The frequencies of circulating CD19(+)CD27(+) memory B cell (Bmem), CD19(+)CD24(high)CD38(high) regulatory B cell (Breg) and the B cell production of interleukin (IL)-10 and interferon (IFN)-gamma were monitored by flow cytometry before and after the treatment. The frequencies of circulating Bregs and the B cell IL-10 production were significantly lower in NMO patients before HDMT compared to healthy controls. Two weeks' HDMT further reduced the frequencies of Bregs while increased the frequencies of Bmems, which steered the numerical balance between Bmem and Breg in favor of Bmem. Meanwhile, HDMT significantly inhibited the B cell IFN-gamma expression. Rituximab exerted its effect through B cell elimination and subsequent B cell repopulation which was characterized by the predominance of Bregs, restored the numerical balance between Breg and Bmem back to an advantageous "Breg > Bmem" status. Therefore, HDMT and rituximab had basically different impacts on B cells in NMO. (C) 2015 Elsevier B.V. All rights reserved.